• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转移性乳腺癌女性患者生存的预后因素以及疾病原发或继发性质对生存的影响:一项基于法国人群的研究

Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study.

作者信息

Marshall Esaie M, Bertaut Aurélie, Desmoulins Isabelle, Darut-Jouve Ariane, Ponnelle Tibor, Poillot Marie-Laure, Beltjens Francoise, Arveux Patrick

机构信息

Côte d'Or Breast Cancer Registry, CGFL, Dijon, France.

Research Unit 4184, Faculty of Medicine, University of Burgundy, Dijon, France.

出版信息

Breast J. 2017 Mar;23(2):138-145. doi: 10.1111/tbj.12717. Epub 2016 Dec 9.

DOI:10.1111/tbj.12717
PMID:27935232
Abstract

We aim to determine whether differences in survival exist between two populations of women with metastatic breast cancer (MBC) and to identify prognostic factors of survival after metastasis diagnosis. Data on women with MBC diagnosed between 2000 and 2011 were provided by the Côte d'Or Breast cancer registry. Survival rates and median overall survival (OS) after metastasis diagnosis were determined using the Kaplan-Meier method and prognostic factors were determined in a Cox proportional hazard model. Overall, 282 women with primary MBC and 340 with secondary MBC were included. A 2-year survival rate was significantly better in women with primary MBC (50.8% [95% CI: 47.8-53.8%] versus 44.5% [95% CI: 41.8-47.2%]). However, median OS did not differ between the two groups (p = 0.1). The prognostic factors associated with worst survival were a triple-negative tumor type (p < 10 ), multiple metastases sites (p < 10 ), an older age at metastasis (p < 10 ), and a SBR grade G3 (p = 0.007). OS between women with primary MBC and women with secondary MBC does not seem to differ significantly. This population-based study provides original epidemiological data on French women without any selection bias inherent to hospital cohorts.

摘要

我们旨在确定两组转移性乳腺癌(MBC)女性患者在生存率上是否存在差异,并找出转移诊断后生存的预后因素。2000年至2011年间确诊的MBC女性患者数据由科多尔乳腺癌登记处提供。采用Kaplan-Meier方法确定转移诊断后的生存率和中位总生存期(OS),并在Cox比例风险模型中确定预后因素。总体而言,纳入了282例原发性MBC女性患者和340例继发性MBC女性患者。原发性MBC女性患者的2年生存率显著更高(50.8% [95% CI:47.8 - 53.8%] 对比44.5% [95% CI:41.8 - 47.2%])。然而,两组之间的中位OS没有差异(p = 0.1)。与最差生存相关的预后因素为三阴性肿瘤类型(p < 0.01)、多个转移部位(p < 0.01)、转移时年龄较大(p < 0.01)以及SBR G3级(p = 0.007)。原发性MBC女性患者和继发性MBC女性患者之间的OS似乎没有显著差异。这项基于人群的研究提供了关于法国女性的原始流行病学数据,没有医院队列固有的任何选择偏倚。

相似文献

1
Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study.转移性乳腺癌女性患者生存的预后因素以及疾病原发或继发性质对生存的影响:一项基于法国人群的研究
Breast J. 2017 Mar;23(2):138-145. doi: 10.1111/tbj.12717. Epub 2016 Dec 9.
2
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.转移性乳腺癌的生存年龄趋势:来自瑞典斯德哥尔摩基于人群的癌症登记处的 26 年纵向数据。
Breast Cancer Res Treat. 2011 Nov;130(2):553-60. doi: 10.1007/s10549-011-1594-z. Epub 2011 May 27.
3
Prognostic factors for survival in metastatic breast cancer by hormone receptor status.激素受体状态对转移性乳腺癌生存的预后因素
Breast Cancer Res Treat. 2014 Jun;145(2):503-11. doi: 10.1007/s10549-014-2964-0. Epub 2014 Apr 26.
4
Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis.年轻女性转移性乳腺癌:一项基于人群的队列研究以描述风险和预后。
Intern Med J. 2014 Aug;44(8):764-70. doi: 10.1111/imj.12481.
5
Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.曲妥珠单抗为基础的治疗用于 HER2 阳性初治或复发的 IV 期乳腺癌女性的临床结局。
Breast. 2014 Feb;23(1):44-9. doi: 10.1016/j.breast.2013.10.005. Epub 2013 Nov 7.
6
Prognostic factors for male breast cancer: similarity to female counterparts.男性乳腺癌的预后因素:与女性相似。
Anticancer Res. 2013 May;33(5):2227-31.
7
Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status.IV期乳腺癌:一项基于人群的关于HER2和HR状态的预后因素研究。
Eur J Cancer Care (Engl). 2015 Nov;24(6):920-8. doi: 10.1111/ecc.12306. Epub 2015 Mar 10.
8
Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival.法国科多尔省乳腺癌生存情况的基于人群的研究:预后因素与相对生存率
Ann Oncol. 2008 Feb;19(2):276-83. doi: 10.1093/annonc/mdm491. Epub 2007 Oct 24.
9
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study.三千年间转移性乳腺癌患者的总生存:COSMO 研究结果。
Clin Breast Cancer. 2021 Oct;21(5):e489-e496. doi: 10.1016/j.clbc.2020.11.001. Epub 2020 Nov 9.
10
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.曲妥珠单抗用于临床实践中HER2阳性转移性乳腺癌的治疗:心脏毒性与总生存期
Eur J Cancer. 2016 Jan;52:41-9. doi: 10.1016/j.ejca.2015.09.012. Epub 2015 Nov 27.

引用本文的文献

1
Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.外泌体包裹的多孔硅纳米颗粒介导的 3,3'-二吲哚甲烷和阿霉素共递送抑制三阴性乳腺癌中癌症干细胞驱动的 EMT。
J Nanobiotechnology. 2024 May 25;22(1):285. doi: 10.1186/s12951-024-02518-0.
2
Reciprocal antagonism of PIN1-APC/C governs mitotic protein stability and cell cycle entry.PIN1-APC/C 的相互拮抗作用控制有丝分裂蛋白的稳定性和细胞周期进入。
Nat Commun. 2024 Apr 15;15(1):3220. doi: 10.1038/s41467-024-47427-w.
3
HR/HER2 de novo metastatic breast cancer: a true peculiar entity?
人表皮生长因子受体2(HER2)原发性转移性乳腺癌:一种真正特殊的实体?
Drugs Context. 2023 Mar 6;12. doi: 10.7573/dic.2022-12-2. eCollection 2023.
4
Prognostic factors for patients with metastatic breast cancer: a literature review.转移性乳腺癌患者的预后因素:文献综述
Transl Cancer Res. 2021 Apr;10(4):1644-1655. doi: 10.21037/tcr-20-2119.
5
Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.新诊断转移性三阴性乳腺癌女性的生存、治疗方案和医疗费用。
Sci Rep. 2022 Jan 14;12(1):729. doi: 10.1038/s41598-021-04316-2.
6
Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review.激素受体阳性/人表皮生长因子受体2阴性(HR+/HER2-)晚期乳腺癌的预后因素:一项系统文献综述
Cancer Manag Res. 2021 Aug 20;13:6537-6566. doi: 10.2147/CMAR.S300869. eCollection 2021.
7
Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus.建立预测 HR 阳性、HER2 阴性转移性乳腺癌患者接受依维莫司治疗的生存预后列线图。
Drug Des Devel Ther. 2021 Aug 10;15:3463-3473. doi: 10.2147/DDDT.S314723. eCollection 2021.
8
Development and validation of a nomogram in survival prediction among advanced breast cancer patients.晚期乳腺癌患者生存预测列线图的开发与验证
Ann Transl Med. 2020 Nov;8(21):1446. doi: 10.21037/atm-20-3473.
9
Clinical and molecular characteristics of secondary breast metastases from primary lung cancer: a study of 22 Chinese cases.原发性肺癌继发性乳腺转移的临床和分子特征:22例中国病例的研究
Int J Clin Exp Pathol. 2020 Jul 1;13(7):1880-1885. eCollection 2020.
10
Prognostic value of routine laboratory variables in prediction of breast cancer recurrence.常规实验室变量对预测乳腺癌复发的预后价值。
Sci Rep. 2017 Aug 15;7(1):8135. doi: 10.1038/s41598-017-08240-2.